What Happened?
Saint Laurent, QC-based Milestone Pharmaceuticals has Appointed Philippe Douville as Chief Executive Officer
About the Company
Milestone was founded in 2005 with the underlying concept to base its drug development programs on clinically validated mechanisms of action in order to mitigate as much drug development risk as possible. The company has raised a total of $34 million in venture capital financing since 2006. At its founding, the company assembled a panel of leading pharmaceutical R&D executives (“drug hunters”) each with an average of 30 years experience in drug development. The drug hunters proposed NCE projects based on clinically proven science to form the basis of Milestone’s drug development programs. Milestone has a seasoned management team with experience in cardiovascular diseases, drug development and business start-ups as well as world-class advisory boards of key opinion leaders with significant expertise in cardiology, regulatory affairs, as well as formulation and drug development.
About the Person
\r\n Philippe Douville is an executive with over 18 years management and entrepreneurial experience in the biotechnology and pharmaceutical industries. He is a founder of Milestone and serves as the company`s Chief Executive Officer. While at Milestone, he raised a total of $34 million in several rounds of equity financing with leading life sciences venture capital firms. Dr. Douville has served as a Director on Milestone`s Board since its inception in 2005 and was Chairman from 2011 to 2012. Prior to Milestone Pharmaceuticals, he held the positions of CEO and Chief Business Officer at Galileo Genomics (later Genizon Biosciences), a population genomics company he co-founded. As the founding CEO, he negotiated Galileo`s seminal strategic alliance with Myriad Genetics that provided the company`s initial funding and subsequently, as Chief Business Officer, he played a key role in preparing the company for its Series A financing. After leaving Galileo in 2001, Dr. Douville was involved in other biotech start-ups including Allostera Pharma. Dr. Douville obtained his Ph.D. in Neuroscience from McGill University (Canada) in 1991 and later pursued several years of post-doctoral research activities at the University of Zurich (Switzerland). He also obtained an MBA from the HEC at the University of Montreal.\r\n
Info Source
News
Short Profile